介质蛋白33:适合用于COPD的生物疗法的标?
1Department of Medical and Surgical Sciences, University "Magna Graecia", Catanzaro, Italy.
介质素-33 (IL-33) /ST2通路在慢性阻塞性肺病 (COPD) 中至关重要. 未来的临床试验结果可能会确定对生物治疗COPD反应最好的患者子组.
科学领域:
- 肺部病理学 肺部病理学
- 免疫学 免疫学 免疫学
- 临床试验 临床试验
背景情况:
- 介素-33 (IL-33) /ST2信号通路在慢性阻塞性肺病 (COPD) 的病理生物学中发挥着重要作用.
- 了解这一轴对于开发针对性治疗COPD至关重要.
- 生物疗法正在成为严重COPD的治疗选择.
更多相关视频
08:16An IL-8 Transiently Transgenized Mouse Model for the In Vivo Long-term Monitoring of Inflammatory Responses
Published on: July 7, 2017
10:39Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy
Published on: April 16, 2019
相关概念视频
Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
COPD: Management Using Bronchodilators and Corticosteroids
COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Chronic Obstructive Pulmonary Disease-I: Introduction
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
